Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes.

Sixteen cycles of Brentuximab vedotin (BV) after autologous stem cell transplant (ASCT) in high-risk relapsed/refractory classical Hodgkin lymphoma demonstrated an improved 2-year progression-free survival (PFS) over placebo. However, most patients are unable to complete all 16 cycles at full dose due to toxicity. This retrospective, multicenter study investigated the effect of cumulative maintenance BV dose on 2-year PFS.

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for Mutation Positive Non-Small Cell Lung Cancer.

Human epidermal growth factor receptor 2 () is a proto-oncogene that, when mutated or overexpressed, plays an important role in oncogenesis. The landscape of -positive breast cancer has changed dramatically over the past 2 decades with the FDA approval of a growing number of agents (antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates) targeting the receptor. inhibition has also been approved for -positive gastric cancer.

Subacute polyneuropathy in a patient undergoing peritoneal dialysis: clinical features and new pathophysiologic insights.

Recently, demyelinating polyneuropathies have been reported in end-stage renal disease patients. These acute and subacute neuropathies share a demyelinating feature and may develop after the initiation of continuous ambulatory peritoneal dialysis. The pathogenesis of these non-chronic forms of neuropathy remains unclear.